Jointly provided by the Johns Hopkins University School of Medicine, the Institute for Johns Hopkins Nursing, and DKBmed.
Volume 6 supported by educational grants from Mylan Specialty L.P, a Viatris Company and Novartis Pharmaceuticals Corporation.
The underrepresentation of racial and ethnic minorities in multiple sclerosis (MS) clinical trials presents significant challenges to the generalizability of the safety and efficacy data of FDA-approved disease-modifying therapies. In this issue of eMS Review, Mima (Jemima) Akinsanya, DO, assistant professor in the Department of Neurology at Georgetown University School of Medicine, explores barriers to minority participation in MS clinical trials, including socioeconomic disadvantages, inadequate outreach, and lack of diverse leadership. The author highlights evidence and recommendations for potential strategies to support greater inclusivity and participation of racial and ethnic minority populations in clinical trials while exploring actional solutions focused on improving logistical support, community engagement, and transparent accountability measures.
Discuss limitations of clinical trials that lack inclusive representation of people from racial and ethnic minority groups.
Assistant Professor, Department of Neurology
Georgetown University Medical Center
Director, Multiple Sclerosis Clinic - Georgetown Neurology at Clinton
Washington, DC
Assistant Professor
Department of Neurology
Johns Hopkins School of Medicine
Baltimore, MD
Assistant Professor
Department of Neurology
Johns Hopkins School of Medicine
Baltimore, MD
Department of Neurology
Johns Hopkins Hospital
Baltimore, MD
1.0 hour Physicians
1.0 contact hour Nurses
Launch date: March 25, 2025
Expiration date: March 24, 2027
